July 26, 2017
During an earnings conference call today, executives from Gilead Sciences disclosed second quarter earnings and projected pipeline goals with a focus on the company’s hepatitis B, hepatitis C and nonalcoholic steatohepatitis treatments.
Product sales for HIV and HBV as a combined market were $3.6 billion in the second quarter of 2017, compared with $3.1 in the same quarter of 2016. According to Robin Washington, company executive vice president and chief financial officer, the increase was primarily due to continued uptake of the company’s Vemlidy (tenofovir alafenamide)-based products. Overall sales increased 11% from the previous quarter.